Fills a gap in current guidance on how to implement humanitarian standards in urban situations. In Arabic, English, French and Spanish available
The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV).
Shoman et al. Globalization and Health (2017) 13:1 DOI 10.1186/s12992-016-0224-2
The document contains preliminary report on all aspects of WHO’s response in the Ebola outbreak. WHO Member States will discuss the report at the sixty-eighth World Health Assembly.
Learning from the Use of Data, Information, and Digital Technologies in the West Africa Ebola Outbreak Response
The Demographic Dividend study on Rwanda assessed the socio-economic and human development potential of our country in the short, medium and long-term period using a comprehensive approach. It generated relevant policy and programme information to guide a well-informed polciy required to propel Rwan...da towards achieving its aspirations of being high middle income country by 2035 and high income country by 2050.
The primary objectives of this study were to assess Rwanda’s prospects for harnessing the demographic dividend and demonstrate priority policy and programme options that the country should adopt in order to optimise its chances of earning a maximum demographic dividend in the context of its youthful population and medium, long-term socio-economic development aspirations.
more
В настоящем отчете (это уже четвертое его издание) анализируются препятствия и факторы, затрудняющие доступ к препаратам для лечения лекарственно-устойчивого туб...ркулеза, в том числе новым и применяющимся по новым показаниям.
more
National Strategic Plan of Ministry of Health 2015-2019
The National Health Plan (NHP) aims to strengthen the country’s health system and pave the way towards Universal Health Coverage (UHC),choosing a path that is explicitly pro-poor. The main goal of NHP 2017-2021 is to extend access to a Basic Essential Package of Health Services (EPHS) to the entir...e population by 2020 while increasing financial protection.
more
Reporting period: January 2014 – December 2014
The human immunodeficiency virus (HIV) epidemic in Myanmar is concentrated among men who have sex with men (MSM), people who inject drugs (PWID) and female sex workers (FSW). HIV prevalence in the adult population aged 15 years and older was esti...mated at 0.54% in 2014. But data from HIV Sentinel Sero-Surveillance (HSS) indicates higher prevalence in 2014 among key populations: FSW 6.3%, MSM 6.6% and PWID 23.1%. Compared to 2012 data, the prevalence has declined from 7.1% in FSW and 8.9% in MSM, but has increased from 18% in PWID.
Epidemiological modelling suggests that in 2014 there were around 212,000 people living with HIV (PLHIV) in Myanmar, 34% of whom were females. Nearly 11,000 people died of HIV-related illnesses, compared to approximately 15,000 in 2011. An estimated 9,000 new infections occurred in 2014.
more
The ‘Toolkit’ is targeted at practitioners responsible for implementing recovery programmes, their objective to provide a ‘how to’ guide on development, implementing and managing complex post-disaster recovery programmes.
Disaster Recovery Toolkit
Disaster Recovery Toolkit
In the aftermath of the April 2015 earthquake in Nepal, this paper looks at lessons drawn from previous comparable disasters and seeks to provide invaluable information and assistance to the operational agencies responding to the crisis.
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more